Penn Researchers Advance Cancer-Prevention Gum After 93% HPV Viral Load Drop
Updated
Updated · WHYY · May 27
Penn Researchers Advance Cancer-Prevention Gum After 93% HPV Viral Load Drop
1 articles · Updated · WHYY · May 27
Penn researchers said a bioengineered chewing gum will enter an HPV clinical trial this year after early saliva tests showed a 93% reduction in HPV viral load.
The gum uses hyacinth-bean-derived FRIL protein to aggregate virus particles and an added antimicrobial peptide to kill cancer-linked oral bacteria before they can infect cells.
A single piece nearly eliminated Porphyromonas gingivalis and Fusobacterium nucleatum, two bacteria tied to oral, head and neck cancers, and researchers say the product also targets fungi.
Penn investigators see the gum as a low-cost preventive tool that could reduce transmission between partners, while separate COVID-19 and influenza studies continue, including a larger London flu trial this summer.
Could this germ-killing gum accidentally create oral superbugs or weaken our long-term natural immunity?
NASA wants this gum for space missions, but can its bio-proteins survive the journey's intense radiation?
Bioengineered Chewing Gum Reduces Oral Cancer-Linked Microbes by Over 90%: Clinical Pathway, Market Potential, and Public Health Impact
Overview
Penn Dental’s Henry Daniell has developed a bioengineered chewing gum that marks a major step forward in oral cancer prevention. Unlike traditional treatments, this gum targets and reduces specific harmful microbes linked to head and neck cancer, while leaving beneficial mouth bacteria unharmed. This selective action not only avoids the side effects of therapies like radiation, which can disrupt healthy microbes and cause problems such as yeast overgrowth, but also opens the door to more effective and affordable therapies. The research highlights a promising new approach that could improve outcomes and accessibility for patients.